Trial Profile
A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Siponimod (Primary)
- Indications Dermatomyositis; Polymyositis
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 29 Oct 2014 New trial record